University of Groningen

Depletion of SAM50 Specifically Targets BCR-ABL-Expressing Leukemic Stem and Progenitor Cells by Interfering with Mitochondrial Functions

Capala, Marta E; Puijs, Maurien; Vellenga, Edo; Schuringa, Jan Jacob

Published in:
Stem cells and development

DOI:
[10.1089/scd.2015.0151](https://doi.org/10.1089/scd.2015.0151)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2016

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Capala, M. E., Puijs, M., Vellenga, E., & Schuringa, J. J. (2016). Depletion of SAM50 Specifically Targets BCR-ABL-Expressing Leukemic Stem and Progenitor Cells by Interfering with Mitochondrial Functions. *Stem cells and development*, 25(5), 427-437. <https://doi.org/10.1089/scd.2015.0151>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Depletion of SAM50 Specifically Targets BCR-ABL-Expressing Leukemic Stem and Progenitor Cells by Interfering with Mitochondrial Functions

Marta E. Capala, Maurien Pruis, Edo Vellenga, and Jan Jacob Schuringa

A high proliferation rate of malignant cells requires an increased energy production, both by anaerobic glucose metabolism and mitochondrial respiration. Moreover, increased levels of mitochondria-produced reactive oxygen species (ROS) promote survival of transformed cells and contribute to the disease progression both in solid tumors and leukemia. Consequently, interfering with mitochondrial metabolism has been used as a strategy to specifically target leukemic cells. SAM50 is a mitochondrial outer membrane protein involved in the formation of mitochondrial intermembrane space bridging (MIB) complex. Although the importance of SAM50 in maintaining MIB integrity and in the assembly of mitochondrial respiratory chain complexes has been described, its specific role in the normal and leukemic hematopoietic cells remains unknown. We observed that human leukemic cells display a specific dependency on SAM50 expression, as downregulation of SAM50 in BCR-ABL-expressing, but not normal CD34⁺ human hematopoietic stem and progenitor cells (HSPCs) caused a significant decrease in growth, colony formation, and replating capacity. Mitochondrial functions of BCR-ABL-expressing HSPCs were compromised, as seen by a decreased mitochondrial membrane potential and respiration. This effect of SAM50 downregulation was recapitulated in normal HSPCs exposed to cytokine-rich culture conditions that stimulate proliferation. Both oncogene-transduced and cytokine-stimulated HSPCs showed increased mitochondrial membrane potential and increased ROS levels compared to their normal counterparts. Therefore, we postulate that human leukemic HSPCs are highly dependent on the proper functioning of mitochondria and that disruption of mitochondrial integrity may aid in targeting leukemic cells.

Introduction

METABOLIC ALTERATIONS ARE ONE of the hallmarks of carcinogenesis. An increased division rate of malignant cells results in elevated energy requirements, and consequently a more active metabolism. The phenomenon known as the Warburg effect describes the propensity of cancer cells to produce lactic acid from glucose even in aerobic conditions [1]. In fact, malignant cells utilize the anaerobic pathway of glucose metabolism next to mitochondrial respiration, which results in an increased glucose consumption rate and increased ATP production [2,3].

As a byproduct of their increased metabolism, tumor cells generate high levels of reactive oxygen species (ROS), with mitochondria being one of the main sources [4–7]. Although elevated ROS levels can be detrimental for both healthy and malignant cells, tumor cells have developed mechanisms to prevent ROS-induced damage.

Cancer cells counteract the overproduction of ROS by upregulating the antioxidant systems to prevent ROS-induced macromolecule damage, senescence, and apoptosis

induction [8–11]. Moreover, large amounts of reduced NADPH that are generated by the upregulated glycolysis pathway scavenge ROS and reduce oxidative stress [12,13]. Consequently, cancer cells can maintain relatively higher ROS levels that are advantageous for tumor progression as they induce a variety of signaling pathways and activate transcription factors that promote growth, survival, and malignant behavior [14–22].

The important role of mitochondrial metabolism for energy production and redox homeostasis has also been described in hematological malignancies. In acute myeloid leukemia (AML), inhibition of mitochondrial translation disrupted the expression of mitochondrial respiratory chain (MRC) complex proteins and decreased respiration, specifically targeting leukemic cells [23]. In CML, deregulated expression of MRC components has been observed in leukemic stem cells (LSCs), indicating an increased level of oxidative phosphorylation that could reflect their high proliferation rate [24]. Elevated ROS levels have also been described in several leukemia models. Leukemic cells expressing internal tandem duplication of FLT3 (FLT3-ITD),

the JAK2 (V617F) activating mutation or the BCR-ABL kinase have shown increased levels of ROS causing DNA double-strand breaks to occur. This in turn has resulted in genomic instability leading to leukemia progression and development of therapy-resistant clones [25–28]. Moreover, elevated ROS levels increased survival of BCR-ABL-expressing cells through the activation of the PI3K/Akt signaling pathway [29].

Recently, RAC2 has been identified as a new key player in maintaining mitochondrial function in leukemic cells. In BCR-ABL-expressing cells, RAC2 has been shown to alter mitochondrial membrane potential and electron flow through the MRC complex III, generating high levels of ROS and causing DNA damage [30]. Downregulation of RAC2 in human BCR-ABL-transformed cord blood (CB) cells and primary blast crisis CML (BC CML) cells resulted in decreased mitochondrial membrane potential and decreased ROS production. Consequently, RAC2-deficient primitive leukemic cells showed increased apoptosis and diminished proliferation and self-renewal [31].

We have identified that RAC2 may be required for the proper functioning of mitochondria due to its direct interaction with mitochondrial transport proteins, such as SAM50 and Metaxin 1 [31]. These proteins, together with Metaxin 2, constitute the sorting and assembly machinery (SAM) in the mitochondrial outer membrane [32–34]. The SAM complex, by interacting with the mitochondrial inner membrane proteins mitofilin and CHCHD3, forms the mitochondrial intermembrane space bridging (MIB) complex involved in the assembly of MRC complexes. Consequently, downregulation of SAM50 was shown to destabilize the MIB complex, causing defective assembly of respiratory complexes and structurally abnormal cristae [35]. The specific role of SAM50 in normal and leukemic hematopoietic cells, however, remains unknown.

In this study, we report that human leukemic cells are specifically dependent on SAM50 expression. Downregulation of SAM50 in BCR-ABL-expressing, but not normal human hematopoietic stem and progenitor cells (HSPCs) cause a dramatic decrease in growth, colony formation, and replating capacity, as well as a decreased mitochondrial membrane potential and respiration. This effect of SAM50 downregulation can be recapitulated in normal HSPCs when exposed to cytokine-rich culture conditions that strongly enhance proliferation. Both oncogene-transduced and cytokine-stimulated HSPCs show increased mitochondrial membrane potential and increased ROS levels compared to their normal counterparts. Therefore, we postulate that human leukemic HSPCs are highly dependent on the proper functioning of mitochondria and that disruption of mitochondrial integrity may aid in targeting leukemic cells.

Materials and Methods

Primary cell isolation and culture conditions

Neonatal CB was obtained from healthy full-term pregnancies after informed consent in accordance with the Declaration of Helsinki from the obstetrics departments of the University Medical Center Groningen (UMCG) and Martini Hospital, Groningen, The Netherlands. All protocols were approved by the Medical Ethics Committee of the UMCG. After separation of mononuclear cells with the lymphocyte

separation medium (PAA Laboratories, Coble, Germany), CD34⁺ cells were isolated using a Magnetically Activated Cell Sorting (MACS) CD34 Progenitor Kit (Miltenyi Biotech, Amsterdam, The Netherlands). For the MS5 coculture experiments, cells were grown in Gartner's medium consisting of α -modified essential medium (α -MEM; Fisher Scientific Europe, Emmergo, The Netherlands) supplemented with 12.5% heat-inactivated fetal calf serum (FCS; Lonza, Leusden, The Netherlands), 12.5% heat-inactivated horse serum (Invitrogen, Breda, The Netherlands), 1% penicillin and streptomycin, 2 mM glutamine (all from PAA Laboratories), 57.2 μ M β -mercaptoethanol (Merck Sharp & Dohme BV, Haarlem, The Netherlands), and 1 μ M hydrocortisone (Sigma-Aldrich Chemie B.V., Zwijndrecht, The Netherlands). Alternatively, cocultures were expanded in Gartner's medium supplemented with 20 ng/mL interleukin-3 (IL-3; Gist-Brocades, Delft, The Netherlands) and stem cell factor (SCF; Amgen, Thousand Oaks, CA).

Cell lines and culture conditions

The 293T embryonic kidney cells (ACC-635; DSMZ, Braunschweig, Germany) and PG13 packaging cells (ATCC CRL-10686, Wesel, Germany) were grown in Dulbecco's modified Eagle's medium (DMEM) with 200 mM glutamine (BioWhittaker, Verie, Belgium) supplemented with 10% FCS and 1% penicillin and streptomycin. K562 myelogenous leukemia cells (ACC-10; DSMZ) were grown in Roswell Park Memorial Institute medium with 200 mM glutamine (BioWhittaker) supplemented with 10% FCS, and 1% penicillin and streptomycin. MS5 murine stromal cells (ACC-441; DSMZ) were grown in α -MEM with 200 mM glutamine (BioWhittaker) supplemented with 10% FCS and 1% penicillin and streptomycin.

Retro- and lentivirus generation and transduction

Stable PG13 producer cell lines of BCR-ABL retroviral constructs were generated and used as published previously [36]. Supernatants from the PG13 cells were harvested after 8–12 h of incubation in human progenitor growth medium (HPGM; Cambrex, Verviers, Belgium) before the retroviral transduction rounds and passed through 0.45- μ m filters (Sigma-Aldrich Chemie B.V.). Before the first transduction round, CD34⁺ CB cells were prestimulated for 48 h in HPGM supplemented with 100 ng/mL SCF, FLT3 Ligand (Flt3L; both from Amgen), and thrombopoietin (TPO; Kirin, Tokyo, Japan). Three rounds of transduction were performed on retronectin-coated 24-well plates in the presence of the same cytokines as for prestimulation and 4 μ g/mL polybrene (Sigma-Aldrich Chemie B.V.). During the last round of retroviral transduction with BCR-ABL, lentiviral short hairpin RNA (shRNA) particles were also added as described below.

shRNA sequences targeting SAM50 were ligated into pHR'rip vector using AcsI and SbfI restriction sites as previously described [31]. For the control, scrambled (SCR) shRNA sequence was used. The 293T embryonic kidney cells were transfected using FuGENE6 (Roche Diagnostics, Almere, The Netherlands) with 3 μ g pCMV Δ 8.91, 0.7 μ g VSV-G, and 3 μ g of pHR'rip vector constructs (shSCR or shSAM50). After 24 h, the medium was changed to HPGM and after 12 h the supernatant containing lentiviral particles was harvested and either stored at -80°C or used fresh for

transduction of target cells. CD34⁺ CB cells were subjected to three rounds of transduction with lentiviral particles, and BCR-ABL-transduced CD34⁺ CB cells were subjected to one round of transduction with lentiviral particles, together with the last round of retroviral transduction, in the presence of prestimulation cytokines and 4 μ g/mL polybrene (Sigma-Aldrich Chemie B.V.) on retronectin-coated 24-well plates (TaKaRa, Tokyo, Japan). K562 cells were subjected to one round of transduction with lentiviral particles in the presence of 4 μ g/mL polybrene, on retronectin-coated 24-well plates. After transduction, transduced green fluorescent protein-positive, truncated nerve growth factor receptor (NGFR)-positive, or double-positive cells were sorted on a MoFlo sorter (Dako Cytomation, Carpinteria, CA).

Long-term cultures on stroma, colony forming cell, and long term culture-initiating cell assay

After sorting, 5×10^4 CB cells or 5×10^3 BCR-ABL cells were plated onto a T25 flask precoated with MS5 stromal cells in 5 mL of Gartner's medium in duplicate. Cocultures were kept at 37°C and 5% CO₂ and cells were demipopulated weekly for analysis. Images of cobblestones were acquired on Leica DMIL inverted phase microscope (Leica Microsystems, Eindhoven, The Netherlands). CFC assays were performed as previously described [37]. For the LTC-IC assay, CB cells were plated in the range of 6–1,458 cells per well in a 96-well plate using Gartner's medium. Methylcellulose (StemCell Technologies, Grenoble, France) supplemented with 20 ng/mL of IL-3, 20 ng/mL of interleukin-6 (IL-6; Gist-Brocades), 20 ng/mL of granulocyte-colony stimulating factor, 20 ng/mL of c-kit ligand (Amgen), and 6 U/mL of erythropoietin (Epo; Cilag, Eprex, Brussels, Belgium) was added at week 5. Two weeks later, wells containing CFCs were scored as positive and the LTC-IC frequency was calculated using L-Cal software (StemCell Technologies). May-Grünwald-Giemsa staining was used to stain cytopins. Cytospin preparations were evaluated and photographed using a Leica DM3000 microscope equipped with a Leica DFC420C digital camera at a total magnification of $\times 400$.

Flow cytometry analyses and sorting

All fluorescence-activated cell sorter (FACS) analyses were performed on a FACSCalibur [Becton-Dickinson (BD), Alpen a/d Rijn, The Netherlands] and data were analyzed using WinList 3D (Verity Software House, Topsham, ME). Cells were sorted on a MoFlo sorter. Antibodies NGFR-APC, CD14-PE, and CD15-APC were obtained from BD.

Measurement of mitochondrial functions

Mitochondrial membrane potential was measured by flow cytometry using hexamethylindodicarbocyanine iodide (DiIC₁; Life Technologies, Bleiswijk, The Netherlands) as described previously [38]. Briefly, 5×10^5 cells were incubated with 50 ng/mL DiIC₁ for 30 min at 37°C, washed twice in phosphate-buffered saline (PBS), and DiIC₁ fluorescence was analyzed by FACS. To measure intracellular ROS levels, staining with CellROX Deep Red reagent was performed according to the manufacturer's protocols (Life Technologies). Fluorescence of the probe was analyzed by FACS. Oxygen consumption rate (OCR) and extracellular

acidification rate (ECAR) were measured on the XF²⁴ Extracellular Flux Analyzer according to the manufacturer's instructions (Seahorse Bioscience, Billerica, MA). Briefly, XF²⁴ Cell Culture Microplate was coated with poly-L-lysine (Sigma-Aldrich Chemie B.V.) and 2.5×10^5 K562 or BCR-ABL CB cells were plated per well in 100 μ L XF Assay Medium (Seahorse Bioscience) supplemented with 4.5 g/L glucose 1 mM sodium pyruvate. Cells were allowed to attach for 30 min and XF Assay Medium was added to the final volume of 700 μ L per well. XF²⁴ Cell Culture Microplate was then loaded into the XF²⁴ Extracellular Flux Analyzer. OCR and ECAR values were derived as a mean of five consecutive measurements.

Immunoblotting

Western blot analysis was performed according to standard protocols. Antibody against SAM50 was kindly provided by Dr. V. Kozjak-Pavlovic (University of Würzburg, Würzburg, Germany). Secondary antibody (goat-anti-rabbit-horseradish peroxidase) was purchased from Dako Cytomation and used in 1:3,000 dilutions. Binding of antibodies was detected by chemiluminescence, according to the manufacturer's instructions (Roche Diagnostics).

Statistical analysis

All values are expressed as mean $\pm$ standard deviation (SD). A two-tailed Student's *t*-test was used for all comparisons. Differences were considered statistically significant at $P < 0.05$.

Results

SAM50 expression is required for the long-term expansion of human BCR-ABL-expressing HSPCs

We have recently identified that the mitochondrial protein SAM50 is a *bona fide* interaction partner of RAC2 [31]. To investigate in more detail the effect of SAM50 downregulation in human leukemic cells, we retrovirally transduced CD34⁺ CB cells to overexpress the BCR-ABL oncogene. Simultaneously, lentiviral transduction with a shRNA-containing construct was performed to downregulate SAM50, and double-transduced cells were sorted and plated in stromal cocultures. The efficiency of SAM50 knockdown was assessed by western blot (Fig. 1A). SAM50-depleted cells reproducibly showed a growth impairment within the first weeks of coculture and a significantly reduced replating capacity (Fig. 1B, C). Although progenitor frequencies assessed by CFC assay directly after sorting and at week 1 of coculture were not significantly lower in SAM50-depleted cocultures, at week 2 they were markedly reduced (Fig. 1D). Importantly, also the replating potential of colony-forming cells was significantly decreased upon SAM50 downregulation (Fig. 1D). Differentiation of SAM50-depleted cells did not differ from the controls and also cell viability, assessed by microscopical evaluation of the cocultures and flow cytometry, was not affected by SAM50 downregulation (data not shown). To further validate these findings, two independent shRNA vectors were generated, and both efficiently downregulated SAM50 at the RNA as well as protein level (Fig. 1E, F). Again, a marked decrease in cumulative

cell counts was observed upon knockdown of SAM50 (Fig. 1G), coinciding with a reduction in cobblestone formation indicating that the most primitive cell fraction was affected by SAM50 downregulation (Fig. 1H). Overall, these data suggested that BCR-ABL-transformed cells require SAM50 expression for their long-term proliferation and self-renewal.

Depletion of SAM50 results in mitochondrial dysfunction in BCR-ABL-expressing HSPCs

Downregulation of SAM50 has been shown to destabilize the MIB complex, causing defective assembly of respiratory complexes [35]. To further investigate whether, in a human leukemia model, SAM50 depletion would result in mitochondrial impairment, we assessed the mitochondrial membrane potential in BCR-ABL-transduced CD34⁺ CB cells upon knockdown of SAM50. FACS analysis using the DiIC mitochondrial dye revealed that depletion of SAM50 caused a marked decrease in the mitochondrial membrane potential in BCR-ABL-transduced HSPCs, in accordance with our previous findings (Fig. 2A) [31]. The DiIC peak was broader than we usually observe, see for instance also Fig. 3F. This was most likely due to the fact that part of the BCR-ABL-expressing cells differentiated along the erythroid lineage as we have seen previously [36]. As a consequence, a heterogeneity of immature cells as well as more mature cells committed toward the erythroid lineage were present in these cultures all displaying different levels of DiIC, and we noted that the decrease in DiIC staining upon SAM50 downregulation was particularly seen in the more immature cells (data not shown). The level of ROS measured in BCR-ABL HSPCs was not significantly altered upon SAM50 downregulation (Fig. 2B).

To investigate whether mitochondrial oxidative phosphorylation was affected by SAM50 depletion, we used the XF^c Analyzer of extracellular flux to measure the OCR and ECAR of the BCR-ABL-expressing leukemic K562 cell line. OCR levels of shSAM50-transduced K562 cells were markedly reduced compared to control shSCR-transduced cells, indicative of decreased mitochondrial respiration. At

the same time, ECAR levels were not significantly changed, indicating that glycolysis was not affected by SAM50 downregulation (Fig. 2C). Subsequently, we measured OCR and ECAR in BCR-ABL and shSAM50 double-transduced CD34⁺ CB cells. Also in this case, the OCR levels were significantly downregulated upon SAM50 depletion, while the decrease in ECAR levels did not reach significance (Fig. 2D). Finally, the two additional independent shRNA SAM50 vectors were also tested in K562 cells and both reduced OCR, while the reduction in ECAR was less pronounced and reached significance only with shSAM50 #2 (Fig. 2E). Overall, these results showed that SAM50 downregulation negatively affected mitochondrial membrane potential and resulted in decreased mitochondrial respiration in BCR-ABL-expressing cells.

Downregulation of SAM50 in normal HSPCs does not affect proliferation, progenitor and stem cell frequencies, or mitochondrial membrane potential, but decreases the replating capacity

Leukemic cells have been proven to be more sensitive to therapeutics targeting mitochondrial metabolism than normal hematopoietic cells [23]. Therefore, we investigated whether downregulation of SAM50 could also be used as a strategy to specifically target leukemic, but not normal hematopoietic cells. To study the long-term effects of SAM50 downregulation in human HSPCs, shRNA-transduced CD34⁺ CB cells were sorted and plated on a bone marrow stromal feeder layer for 5 weeks. The efficiency of SAM50 downregulation in shRNA-transduced cells was assessed by western blot (Fig. 3A). During the coculture, SAM50-depleted cells showed no proliferative disadvantage compared to control shSCR-transduced cells (Fig. 3B).

Differentiation along the myeloid lineage was also unaffected (Fig. 3C). In addition, SAM50 downregulation did not result in a significant decrease in progenitor frequency as assessed by CFC assay using cells directly after transduction and sorting (Fig. 3D, week 0) or by using cells taken at week 1 from MS5 cocultures shown in Fig. 3B. Only a slight reduction in CFCs was noted using cells taken at week 2

FIG. 1. Human BCR-ABL-transduced HSPCs depend on SAM50 expression for their long-term expansion. (A) Cord blood (CB) CD34⁺ stem/progenitor cells were cotransduced with a retroviral construct for BCR-ABL and either a control scrambled shRNA vector (shSCR) or with SAM50-targeting shRNA vectors (shSAM50). Transduced cells were sorted and used for western blot analysis to determine SAM50 protein levels. Quantification of protein expression relative to control is indicated above each lane. (B) CB CD34⁺ stem/progenitor cells were cotransduced with BCR-ABL and either control shSCR or with shSAM50. 5×10^3 double-transduced cells were sorted per group and plated on MS5 stromal cells. Cultures were semi-depopulated on indicated days for analysis and replated as indicated. The cumulative cell growth is shown for a representative experiment out of four independent experiments. (C) Fold reduction of cumulative cell growth of BCR-ABL and shSAM50-transduced CD34⁺ CB cells in long-term coculture as described in panel B, normalized to control cells. Cumulative expansion curves of four independent experiments are shown. The arrows indicate that leukemic cells were harvested from cocultures and replated onto new MS5 stromal cells. (D) Suspension cells from MS5 cocultures as described in panel B were analyzed for progenitor frequency by CFC assay. The 10^4 cells from each coculture were plated in a CFC assay in methylcellulose in duplicate, and colonies were evaluated 2 weeks after plating. CFC cells were then harvested and 10^5 cells were replated to form secondary CFCs. Total CFC numbers are shown from a representative of three independent experiments. Error bars indicate SD. * $P < 0.05$. (E, F) Two independent shRNA vectors #2 and #3 were generated, which efficiently downmodulated SAM50 as determined by quantitative real-time polymerase chain reaction (E) or by western blotting (F). (G) Coculture experiments as in (B) and (C) with BCR-ABL/shRNA vector transduced cells. Control cultures are normalized to one and the average of three experiments is shown. (H) Examples of day 14 cobblestones formed within the coculture by shSCR- and shSAM50 #2/3-transduced BCR-ABL cells. HSPCs, hematopoietic stem and progenitor cells; SD, standard deviation; shRNA, short hairpin RNA.

from MS5 cocultures (Fig. 3D). Similarly, no differences were seen in the most primitive stem cell fraction upon SAM50 knockdown as determined by LTC-IC assays (1:302 vs. 1:224, $P=0.4$, Fig. 3E). Also, the mitochondrial functions as assessed by the measurement of the mitochondrial membrane potential and ROS levels were not different between SAM50-depleted and control HSPCs (Fig. 3F, G). However, the replating capacity of colony-forming cells was significantly reduced upon SAM50 downregulation, suggesting that under stress conditions SAM50 also becomes important in normal cells (Fig. 3D).

BCR-ABL-transduced human HSPCs show increased mitochondrial activity

We speculated that the high sensitivity of BCR-ABL-expressing cells to SAM50 downregulation could originate from their increased mitochondrial activity. To this end, we directly compared mitochondrial membrane potential and ROS levels in normal and BCR-ABL-expressing human HSPCs. CD34⁺ cells isolated from a single batch of CB were used to eliminate interbatch variability, and either cotransduced with BCR-ABL and shRNA constructs, or

transduced with shRNA only. Sorted cells were plated in stromal cocultures and FACS analyses were performed at the same time for normal and BCR-ABL-transduced cells. FACS analysis of DiIC dye showed that the mitochondrial membrane potential significantly increased in BCR-ABL-expressing HSPCs, compared to controls (Fig. 4A). ROS levels in BCR-ABL HSPCs were also increased, although to levels that were not statistically significant (Fig. 4B). Overall, these data indicate that the mitochondrial activity of leukemic cells is altered in comparison to normal CD34⁺ cells.

Cytokine-driven proliferation of normal HSPCs results in increased mitochondrial activity and increased sensitivity to SAM50 downregulation

The BCR-ABL oncogene is a potent driver of proliferation of transformed CB cells [36,39]. Therefore, we wondered whether inducing a high proliferation rate on CB CD34⁺ cells by culturing them in a cytokine-rich medium would increase their mitochondrial activity and render them

more sensitive to SAM50 depletion. CD34⁺ CB cells were cultured in a coculture setting with or without the addition of cytokines (20 ng/mL SCF and IL-3). As expected, cells cultured with cytokines showed an increased proliferation rate (compare shSCR control data in Fig. 3B without cytokines with data in Fig. 5D with cytokines). FACS analysis using DiIC staining showed a significant increase in mitochondrial membrane potential in cells cultured with the addition of cytokines (Fig. 5A). Also the ROS levels produced within these cells were increased, although the results did not reach statistical significance (Fig. 5B). OCR levels were significantly increased upon the addition of cytokines (Fig. 5C). Together, this showed that the cytokine-induced proliferation is paralleled by increased mitochondrial activity in CB cells.

Next, we transduced CD34⁺ CB cells with the SAM50-targeting or shSCR control shRNA construct, and transduced cells were sorted and plated on stroma in the same cytokine-rich medium. Under the proliferation-driven culture conditions, shSAM50-transduced CB cells showed a

FIG. 2. Depletion of SAM50 causes mitochondrial dysfunction in BCR-ABL-expressing HSPCs. (A) The 5×10^3 CB CD34⁺ stem/progenitor cells cotransduced with BCR-ABL and either control scrambled shRNA vector (shSCR) or with SAM50-targeting shRNA vectors (shSAM50) as well were sorted and plated on MS5 stromal cells. Suspension cells were harvested after 14 days of coculture and stained with DiIC to measure changes in mitochondrial membrane potential. Representative FACS plots and quantification of FACS measurements are shown, represented as changes in MFI relative to control. Average of three independent experiments is shown with SD. (B) Suspension cells from the double-transduced cocultures (BCR-ABL and shSCR or shSAM50) were harvested after 14 days and stained with CellROX to measure oxidative stress. Representative FACS plot and quantification of FACS measurements are shown, represented as changes in MFI relative to control. Average of three independent experiments is shown with SD. (C) K562 cells were transduced with either shSCR or shSAM50 and analyzed by the XF^e Analyzer of extracellular flux. OCR and ECAR are represented as changes relative to control. Average of three independent experiments is shown with SD. (D) Suspension cells from the double-transduced cocultures (BCR-ABL and shSCR or shSAM50) as described in panel A were harvested after 14 days and analyzed by the XF^e Analyzer of extracellular flux. OCR and ECAR are represented as change relative to control. Average of three independent experiments is shown with SD. (E) OCR and ECAR measurements in K562 cells as in (C), but now with the independent shSAM50 vectors #2 and #3. ECAR, extracellular acidification rate; FACS, fluorescence-activated cell sorter; MFI, mean fluorescence intensity; OCR, oxygen consumption rate. * $P < 0.05$, *** $P < 0.001$.

FIG. 3. SAM50 downregulation affects replating capacity, but not proliferation or progenitor and stem cell frequencies of human HSPCs in stromal cocultures. **(A)** CB CD34⁺ stem/progenitor cells were transduced with control scrambled shRNA vector (shSCR) or with SAM50-targeting shRNA vectors (shSAM50). Transduced cells were sorted and used for western blot analysis to determine SAM50 protein levels. Quantification of protein expression relative to control is indicated above each lane. **(B)** The 5×10^4 transduced and sorted cells per group were plated on MS5 stromal cells and kept in the coculture for 5 weeks; cultures were demi-depopulated weekly for analysis. Weekly cumulative cell growth is shown for a representative experiment of four independent experiments. **(C)** Suspension cells from MS5 cocultures as described in *panel B* were analyzed for the expression of myeloid surface markers at week 2 of coculture. Distribution of differentiation **(D)** Suspension cells from MS5 cocultures as described in *panel B* were analyzed for progenitor frequency by CFC assay. The 10^4 cells from each coculture were plated in a CFC assay in methylcellulose in duplicate, and colonies were evaluated 2 weeks after plating. CFC cells were then harvested and 10^5 cells were replated to form secondary CFCs. CFU-GM and BFU-E numbers are shown from a representative of three independent experiments; error bars indicate SD. **(E)** LTC-IC frequencies were determined in limiting dilution on MS5 stromal cells. After 5 weeks of culture, methylcellulose was added and colonies were scored 2 weeks later. Poisson statistics were used to calculate LTC-IC frequencies. **(F)** Suspension cells from the cocultures as described in *panel B* were harvested after 14 days and stained with DiIC to measure changes in mitochondrial membrane potential. Representative FACS plots and quantification of FACS measurements are shown, represented as changes in MFI relative to control. Average of three independent experiments is shown with SD. **(G)** Suspension cells from the cocultures as described in *panel B* were harvested after 14 days and stained with CellROX to measure oxidative stress. Representative FACS plot and quantification of FACS measurements are shown, represented as changes in MFI relative to control. Average of three independent experiments is shown with SD. BFU-E, burst-forming unit-erythroid; CFU-GM, colony-forming unit-granulocyte-macrophage. * $P < 0.05$, *** $P < 0.001$.

FIG. 4. Increased mitochondrial activity of BCR-ABL-transduced human HSPCs. **(A)** CB CD34⁺ stem/progenitor cells were transduced with either control or BCR-ABL and were plated on MS5 stromal cells. Suspension cells were harvested after 14 days of coculture and stained with DiIC to measure changes in mitochondrial membrane potential. Representative FACS plot and quantification of FACS measurements are shown, represented as changes in MFI relative to control. Average of three independent experiments is shown with SD. **(B)** Suspension cells from the cocultures as described in *panel A* were harvested after 14 days and stained with CellROX to measure oxidative stress. Representative FACS plot and quantification of FACS measurements are shown, represented as changes in MFI relative to control. Average of three independent experiments is shown with SD. *** $P < 0.001$.

significant proliferative disadvantage, which was not seen in the regular CB cocultures without the extra addition of cytokines (Figs. 5D and 3B). Also the mitochondrial membrane potential was significantly decreased and ROS levels were slightly, but not significantly, reduced (Fig. 5E, F). Overall, these data suggest that a high proliferation rate induced by cytokines increased the mitochondrial activity in CB cells, which correlated with an increased sensitivity to SAM50 downregulation.

Discussion

Interfering with mitochondrial metabolism has previously been shown to be an effective strategy to specifically target leukemic cells. In AML cells, inhibition of mitochondrial translation with the drug tigecycline or by shRNA-mediated knockdown of the EF-Tu mitochondrial translation factor showed a selective antileukemic effect [23]. In chronic lymphocytic leukemia, interrupting the MRC by a benzodiazepine derivative PK11195 specifically induced cell death in leukemic, but not normal T and B cells [40]. Also, in BCR-ABL-expressing leukemic cells pharmacological inhibition or decreased expression of small GTPase RAC2 selectively targeted leukemic and not normal HSPCs by decreasing their mitochondrial activity and ROS production [30,31,41,42].

In the current study we show that shRNA-mediated downregulation of a mitochondrial protein SAM50 resulted in a strongly reduced proliferation of leukemic but not normal human HSPCs, using multiple independent shRNAs against SAM50. The replating capacity of leukemic cells both in coculture and CFC assay was strongly decreased, suggesting that also the more primitive, LSC-containing population was affected. Also the mitochondrial functions such as OCR were affected by SAM50 downregulation in BCR-ABL expressing, but not normal CB cells.

SAM50, as a part of the MIB complex, is necessary for the assembly of the MRC and formation of cristae [35]. In agreement with this, our experiments showed that downregulation of SAM50 resulted not only in a decreased mi-

tochondrial membrane potential in BCR-ABL-expressing human HSPCs, but also lower OCR, indicative of decreased oxidative phosphorylation. SAM50 expression was not increased in AML CD34⁺ cells as compared to normal bone marrow CD34⁺ cells (unpublished observation) and, therefore, could not account for the dependence of leukemic cells on SAM50. When we directly compared normal and BCR-ABL-transduced CB CD34⁺ cells, we observed an increased mitochondrial membrane potential and (although not statistically significant) increased ROS levels. This was in accordance with previous findings, where increased mitochondrial biogenesis and increased respiratory rates were shown to be characteristic for leukemic cells [23,40]. Thus, we concluded that an increase in mitochondrial activity of leukemic cells makes them more vulnerable to strategies disrupting mitochondrial functions.

Although, in the steady state, the proliferation and progenitor frequency of normal CB cells in coculture was not affected by SAM50 downregulation, the replating capacity of progenitor cells was strongly reduced. This suggests that upon stress, possibly due to increased energy requirements, cells rely more strongly upon intact mitochondrial functions. Malignant transformation, with its increased proliferation and metabolic rate, also creates stress within the cells. Moreover, accumulation of ROS results in the so-called cancer-associated oxidative stress [20]. Although elevated ROS levels can be advantageous for malignant cells by inducing prosurvival signaling pathways, too high ROS cause detrimental DNA and protein damage [43]. Therefore, disruption of the redox balance in either direction can negatively affect growth and survival of transformed cells.

Addition of cytokines to the coculture medium not only increased the proliferation rate of normal CB cells, but also rendered them more sensitive to SAM50 downregulation. This effect could not only simply be a result of a higher proliferation rate that requires more energy produced by the mitochondria, but also a direct effect of cytokine signaling. Several growth factors and cytokines, including IL-3, were found to stimulate ROS production [44,45]. In accordance with that, in our study we found not only increased

FIG. 5. Increased mitochondrial activity and increased sensitivity to SAM50 downregulation in normal HSPCs upon cytokine stimulation. (A) The 5×10^4 CB CD34⁺ stem/progenitor cells were plated on MS5 stromal cells in Gartner's medium with or without the addition of cytokines (20 ng/mL SCF and IL-3). Suspension cells were harvested after 14 days of coculture and stained with DiIC to measure changes in mitochondrial membrane potential. Representative FACS plot and quantification of FACS measurements are shown, represented as changes in MFI relative to control. Average of three independent experiments is shown with SD. (B) Suspension cells from the cocultures as described in panel A were harvested after 14 days and stained with CellROX to measure oxidative stress. Representative FACS plot and quantification of FACS measurements are shown, represented as changes in MFI relative to control. Average of three independent experiments is shown with SD. (C, D) CB CD34⁺ cells were transduced with control shSCR or with shSAM50 vectors, and 5×10^4 transduced and sorted cells per group were plated on MS5 stromal cells and kept in the coculture for 5 weeks, in medium supplemented with cytokines. Cocultures were semi-depopulated weekly for analysis. Weekly cumulative cell growth is shown as an average of three independent experiments. * $P < 0.05$, ** $P < 0.01$. (E) Suspension cells from cocultures like described in panel C were harvested after 14 days of coculture and stained with DiIC to measure changes in mitochondrial membrane potential. Representative FACS plot and quantification of FACS measurements are shown, represented as changes in MFI relative to control. Average of three independent experiments is shown with SD. (F) Suspension cells from the cocultures as described in panel C were harvested after 14 days and stained with CellROX to measure oxidative stress. Representative FACS plot and quantification of FACS measurements are shown, represented as changes in MFI relative to control. Average of three independent experiments is shown with SD. * $P < 0.05$, ** $P < 0.01$.

mitochondrial membrane potential, but also increased, although not statistically significant, ROS levels in cytokine-stimulated CB cells. Although the effect of SAM50 downregulation on the growth of CB cells in cytokine-rich cultures was clear, it was less dramatic than in BCR-ABL-transduced CB cells. This suggests that driving cell prolifer-

ation is not the only aspect of the oncogenic kinase activity that is responsible for the increased sensitivity to SAM50 downregulation. Elucidating these additional mechanisms that make leukemic cells highly dependent on mitochondrial functions could contribute to more efficient and selective targeting of leukemia.

Acknowledgments

The authors would like to thank Dr. Vera Kozjak-Pavlovic from the University of Würzburg, Germany for kindly providing anti-SAM50 antibody, as well as all the members of the Experimental Hematology Laboratory for helpful discussions. The authors thank Jeanet Dales for help with CB isolations. This work was supported by a grant from The Netherlands Organization for Scientific Research (NWO-VIDI 91796312) to J.J.S.

Author Disclosure Statement

No competing financial interests exist.

References

- Racker E. (1972). Bioenergetics and the problem of tumor growth. *Am Sci* 60:56–63.
- Koppenol WH, PL Bounds and CV Dang. (2011). Otto Warburg's contributions to current concepts of cancer metabolism. *Nat Rev Cancer* 11:325–337.
- Warburg O, F Wind and E Negelein. (1927). The metabolism of tumors in the body. *J Gen Physiol* 8:519–530.
- Boveris A and B Chance. (1973). The mitochondrial generation of hydrogen peroxide. General properties and effect of hyperbaric oxygen. *Biochem J* 134:707–716.
- Bonora E, AM Porcelli, G Gasparre, A Biondi, A Ghelli, V Carelli, A Baracca, G Tallini, A Martinuzzi, et al. (2006). Defective oxidative phosphorylation in thyroid oncogenic carcinoma is associated with pathogenic mitochondrial DNA mutations affecting complexes I and III. *Cancer Res* 66:6087–6096.
- Carew JS, ST Nawrocki, RH Xu, K Dunner, DJ McConkey, WG Wierda, MJ Keating and P Huang. (2004). Increased mitochondrial biogenesis in primary leukemia cells: the role of endogenous nitric oxide and impact on sensitivity to fludarabine. *Leukemia* 18:1934–1940.
- Turrens JF. (2003). Mitochondrial formation of reactive oxygen species. *J Physiol* 552:335–344.
- Bae YS, SW Kang, MS Seo, IC Baines, E Tekle, PB Chock and SG Rhee. (1997). Epidermal growth factor (EGF)-induced generation of hydrogen peroxide. Role in EGF receptor-mediated tyrosine phosphorylation. *J Biol Chem* 272:217–221.
- Sundaresan M, ZX Yu, VJ Ferrans, K Irani and T Finkel. (1995). Requirement for generation of H₂O₂ for platelet-derived growth factor signal transduction. *Science* 270:296–299.
- Vaughn AE and M Deshmukh. (2008). Glucose metabolism inhibits apoptosis in neurons and cancer cells by redox inactivation of cytochrome c. *Nat Cell Biol* 10:1477–1483.
- Schafer ZT, AR Grassian, L Song, Z Jiang, Z Gerhart-Hines, HY Irie, S Gao, P Puigserver and JS Brugge. (2009). Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. *Nature* 461:109–113.
- Anastasiou D, G Pouligiannis, JM Asara, MB Boxer, JK Jiang, M Shen, G Bellinger, AT Sasaki, JW Locasale, et al. (2011). Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. *Science* 334:1278–1283.
- Hamanaka RB, NS Chandel. (2011). Cell biology. Warburg effect and redox balance. *Science* 334:1219–1220.
- Meyer M, HL Pahl and PA Baeuerle. (1994). Regulation of the transcription factors NF- κ B and AP-1 by redox changes. *Chem Biol Interact* 91:91–100.
- Sun Y and LW Oberley. (1996). Redox regulation of transcriptional activators. *Free Radic Biol Med* 21:335–348.
- Ding M, JJ Li, SS Leonard, JP Ye, X Shi, NH Colburn, V Castranova and V Vallyathan. (1999). Vanadate-induced activation of activator protein-1: role of reactive oxygen species. *Carcinogenesis* 20:663–668.
- Wang S, SS Leonard, J Ye, M Ding and X Shi. (2000). The role of hydroxyl radical as a messenger in Cr(VI)-induced p53 activation. *Am J Physiol Cell Physiol* 279:C868–C875.
- Gao P, H Zhang, R Dinavahi, F Li, Y Xiang, V Raman, ZM Bhujwalla, DW Felsher, L Cheng, et al. (2007). HIF-dependent antitumorigenic effect of antioxidants in vivo. *Cancer Cell* 12:230–238.
- Bell EL, BM Emerling and NS Chandel. (2005). Mitochondrial regulation of oxygen sensing. *Mitochondrion* 5:322–332.
- Trachootham D, J Alexandre and P Huang. (2009). Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? *Nat Rev Drug Discov* 8:579–591.
- Kumar B, A Kumar, BN Pandey, KP Mishra and B Hazra. (2009). Role of mitochondrial oxidative stress in the apoptosis induced by diospyrin diethylether in human breast carcinoma (MCF-7) cells. *Mol Cell Biochem* 320:185–195.
- Hanahan D and RA Weinberg. (2011). Hallmarks of cancer: the next generation. *Cell* 144:646–674.
- Skrtic M, S Sriskanthadevan, B Jhas, M Gebbia, X Wang, Z Wang, R Hurren, Y Jitkova, M Gronda, et al. (2011). Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia. *Cancer Cell* 20:674–688.
- Flis K, D Irvine, M Copland, R Bhatia and T Skorski. (2012). Chronic myeloid leukemia stem cells display alterations in expression of genes involved in oxidative phosphorylation. *Leuk Lymphoma* 53:2474–2478.
- Sallmyr A, J Fan, K Datta, KT Kim, D Grosu, P Shapiro, D Small and F Rassool. (2008). Internal tandem duplication of FLT3 (FLT3/ITD) induces increased ROS production, DNA damage, and misrepair: implications for poor prognosis in AML. *Blood* 111:3173–3182.
- Sattler M, S Verma, G Shrikhande, CH Byrne, YB Pride, T Winkler, EA Greenfield, R Salgia and JD Griffin. (2000). The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. *J Biol Chem* 275:24273–24278.
- Koptyra M, K Cramer, A Slupianek, C Richardson and T Skorski. (2008). BCR//ABL promotes accumulation of chromosomal aberrations induced by oxidative and genotoxic stress. *Leukemia* 22:1969–1972.
- Nowicki MO, R Falinski, M Koptyra, A Slupianek, T Stoklosa, E Gloc, M Nieborowska-Skorska, J Blasiak and T Skorski. (2004). BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks. *Blood* 104:3746–3753.
- Naughton R, C Quiney, SD Turner and TG Cotter. (2009). Bcr-Abl-mediated redox regulation of the PI3K/AKT pathway. *Leukemia* 23:1432–1440.
- Nieborowska-Skorska M, PK Kopinski, R Ray, G Hoser, D Ngaba, S Flis, K Cramer, MM Reddy, M Koptyra, et al. (2012). Rac2-MRC-cIII-generated ROS cause genomic

- instability in chronic myeloid leukemia stem cells and primitive progenitors. *Blood* 119:4253–4263.
31. Capala ME, H Maat, F Bonardi, V van den Boom, J Kuipers, E Vellenga, BN Giepmans and JJ Schuringa. (2015). Mitochondrial dysfunction in human leukemic stem/progenitor cells upon loss of RAC2. *PLoS One* 10:e0128585.
 32. Humphries AD, IC Streimann, D Stojanovski, AJ Johnston, M Yano, NJ Hoogenraad and MT Ryan. (2005). Dissection of the mitochondrial import and assembly pathway for human Tom40. *J Biol Chem* 280:11535–11543.
 33. Kozjak-Pavlovic V, K Ross, N Benlasfer, S Kimmig, A Karlas and T Rudel. (2007). Conserved roles of Sam50 and metaxins in VDAC biogenesis. *EMBO Rep* 8:576–582.
 34. Kozjak V, N Wiedemann, D Milenkovic, C Lohaus, HE Meyer, B Guiard, C Meisinger and N Pfanner. (2003). An essential role of Sam50 in the protein sorting and assembly machinery of the mitochondrial outer membrane. *J Biol Chem* 278:48520–48523.
 35. Ott C, K Ross, S Straub, B Thiede, M Goetz, C Goosmann, M Krischke, MJ Mueller, G Krohne, et al. (2012). Sam50 functions in mitochondrial intermembrane space bridging and biogenesis of respiratory complexes. *Mol Cell Biol* 32:1173–1188.
 36. Rizo A, SJ Horton, S Olthof, B Dontje, A Ausema, R van Os, V van den Boom, E Vellenga, G de Haan, et al. (2010). BMI1 collaborates with BCR-ABL in leukemic transformation of human CD34+ cells. *Blood* 116:4621–4630.
 37. Schuringa JJ, KY Chung, G Morrone and MA Moore. (2004). Constitutive activation of STAT5A promotes human hematopoietic stem cell self-renewal and erythroid differentiation. *J Exp Med* 200:623–635.
 38. Zamora M, C Merono, O Vinas and T Mampel. (2004). Recruitment of NF-kappaB into mitochondria is involved in adenine nucleotide translocase 1 (ANT1)-induced apoptosis. *J Biol Chem* 279:38415–38423.
 39. Chalandon Y, X Jiang, G Hazlewood, S Loutet, E Conneally, A Eaves and C Eaves. (2002). Modulation of p210(BCR-ABL) activity in transduced primary human hematopoietic cells controls lineage programming. *Blood* 99:3197–3204.
 40. Jitschin R, AD Hofmann, H Bruns, A Giessel, J Bricks, J Berger, D Saul, MJ Eckart, A Mackensen, et al. (2014). Mitochondrial metabolism contributes to oxidative stress and reveals therapeutic targets in chronic lymphocytic leukemia. *Blood* 123:2663–2672.
 41. Capala ME, E Vellenga and JJ Schuringa. (2014). ELMO1 is upregulated in AML CD34+ stem/progenitor cells, mediates chemotaxis and predicts poor prognosis in normal karyotype AML. *PLoS One* 9:e111568.
 42. Sengupta A, J Arnett, S Dunn, DA Williams and JA Cancelas. (2010). Rac2 GTPase deficiency depletes BCR-ABL+ leukemic stem cells and progenitors in vivo. *Blood* 116:81–84.
 43. Cairns RA, IS Harris and TW Mak. (2011). Regulation of cancer cell metabolism. *Nat Rev Cancer* 11:85–95.
 44. Maraldi T, C Prata, SF Vieceli Dalla, C Caliceti, L Zamboni, D Fiorentini and G Hakim. (2009). NAD(P)H oxidase isoform Nox2 plays a prosurvival role in human leukaemia cells. *Free Radic Res* 43:1111–1121.
 45. Zhou F, Q Shen and FX Claret. (2013). Novel roles of reactive oxygen species in the pathogenesis of acute myeloid leukemia. *J Leukoc Biol* 94:423–429.

Address correspondence to:

Prof. Jan Jacob Schuringa

Department of Experimental Hematology

Cancer Research Center Groningen (CRCG)

University Medical Center Groningen

University of Groningen

Hanzeplein 1

Groningen 9713 GZ

The Netherlands

E-mail: j.j.schuringa@umcg.nl

Received for publication April 24, 2015

Accepted after revision, January 5, 2016

Prepublished on Liebert Instant Online January 6, 2016